ATLAB Pharma, BZL Biologics sign agreement for radiopharmaceutical Lu-J591.
M2 PHARMA-October 31, 2011-ATLAB Pharma, BZL Biologics sign agreement for radiopharmaceutical Lu-J591(C)2011 M2 COMMUNICATIONS
31 October 2011 - French biotech ATLAB Pharma SAS and US BZL Biologics LLC have signed an exclusive sublicence agreement to develop, manufacture and distribute 177Lu-J591, a radiopharmaceutical for cancer treatment.
Under the agreement, the partners will perform a Phase IIb/III clinical validation programme. ATLAB will fund certain product development and clinical studies.
So far, 177Lu-J591 has been tested in Phase I and Phase II trials in 108 patients with metastatic castrate-resistant prostate cancer (M+ CRPC) and it has proved to be well tolerated and with attractive efficacy.
A multi-centre, randomised Phase IIb clinical trial is currently in progress to test the drug in castrate-resistant prostate cancer (CRPC) patients with rising PSA but no detectable metastasis (M0CRPC).
((Comments on this story may be sent to email@example.com))